Vancouver, Canada – February 21, 2025 – Augurex Life Sciences Corp., a leader in autoimmune biomarker-based diagnostics, today announced its participation in the Tennessee Rheumatology Society (TRS) 2025 Annual Meeting taking place from February 28 – March 1 in Nashville, TN. This event brings together leading rheumatologists, researchers, and industry experts to discuss the latest developments in rheumatic disease diagnostics and treatment strategies.
Augurex will be exhibiting alongside its collaborators, New Day Diagnostics, to showcase their Anti-14-3-3eta Multiplex test—the first-in-class diagnostic blood test for axial spondyloarthritis (axSpA).
Despite advances in rheumatology, early detection and disease management remain a challenge in diseases like rheumatoid arthritis (RA) and axSpA. Augurex is dedicated to improving diagnostic accuracy through biomarker-driven solutions, including:
- 14-3-3eta Biomarker for RA – Supports early detection and disease activity monitoring
- Anti-14-3-3eta Multiplex Biomarker for axSpA – The first and only diagnostic biomarker for axSpA, providing valuable insights to help guide treatment decisions
If you’re attending TRS 2025, we invite you to connect with us to discuss how biomarkers are advancing precision medicine and patient outcomes.
Learn more about the event here:
TRS 2025 Annual Meeting
About Augurex
Augurex is a commercial-stage diagnostics company dedicated to the early identification and diagnosis of autoimmune disorders, allowing treatment options to be optimized and personalized for patients around the world. Augurex’s lead diagnostic test which detects the 14-3-3eta protein, available as JOINTstat® in Canada, is an important tool in the diagnosis and management of inflammatory diseases, including rheumatoid arthritis. The analyte-specific reagents to detect 14-3-3eta are available for purchase and use by U.S. clinical laboratories as a component of diagnostic tests developed by such laboratories. The Anti-14-3-3eta Multiplex ASRs expand Augurex’s biomarker-informed diagnostic autoimmune solutions into axial spondyloarthritis, an autoimmune disease often misdiagnosed as low back pain, and which if untreated can lead to impaired spinal mobility and fusion of the vertebrae. Learn more about Augurex at www.augurex.com and follow us on Facebook, LinkedIn and X.
Media Contact
Nima Mazinani
(604) 674-8231
[email protected]